Wezlana
Active Ingredient(s): Ustekinumab-auubFDA Approved: * October 31, 2023
Pharm Company: * AMGEN INC
Category: Immunosuppressive
Ustekinumab, sold under the brand name Stelara is a monoclonal antibody medication developed by Janssen Pharmaceuticals, for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis,[5] targeting both IL-12 and IL-23.[6] Ustekinumab is approved to treat Crohn's disease in the United States, Israel, Australia, and the European Union (EU), and ulcerative colitis in the US, and in the EU to patients who have not responded to m... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.Dosage List
Wezlana 45 mg/.5ml Subcutaneous Injection, Solution
NDC: 84612-055
Labeler:
Optum Health Solutions (Ireland) Limited
Wezlana 130 mg/26ml Intravenous Injection, Solution
NDC: 84612-066
Labeler:
Optum Health Solutions (Ireland) Limited
Wezlana 45 mg/.5ml Subcutaneous Injection, Solution
NDC: 84612-076
Labeler:
Optum Health Solutions (Ireland) Limited
Wezlana 90 mg/ml Subcutaneous Injection, Solution
NDC: 84612-089
Labeler:
Optum Health Solutions (Ireland) Limited
Wezlana 45 mg/.5ml Subcutaneous Injection, Solution
NDC: 84612-855
Labeler:
Optum Health Solutions (Ireland) Limited
Wezlana 45 mg/.5ml Subcutaneous Injection, Solution
NDC: 84612-876
Labeler:
Optum Health Solutions (Ireland) Limited
Wezlana 90 mg/ml Subcutaneous Injection, Solution
NDC: 84612-889
Labeler:
Optum Health Solutions (Ireland) Limited